AMG 410 alone or with other drugs for KRAS-altered advanced cancers
Treatments studied
Part of Cancer, Digestive system, Lungs & breathing clinical trials.
This study tests a new drug called AMG 410 by itself or with other medicines in people whose cancer has a specific change in the KRAS gene. It is for advanced or metastatic solid tumors that have not responded to standard treatments or who have chosen not to take them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old (or older if required by your country).
- Your cancer must have a KRAS gene change (mutation or extra copies) confirmed by a test.
- You must no longer have standard treatment options or have decided not to take them.
- You should be able to swallow and hold down pills.
- You must be in fairly good health (able to do light activities like walking or chores).
- Your tumor must be measurable (doctors can track its size on scans).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (ASP5834) for people with advanced solid tumors that have changes in the KRAS gene. The study looks for a safe and effective dose, and may help you if your standard treatments have stopped working.
This Phase 1 trial tests ASP3082 in adults with advanced or metastatic solid tumors that have a KRAS G12D mutation. It may help people whose standard targeted treatments are no longer working, or who cannot receive standard approved therapies.
This trial tests whether RMC-6236 can treat advanced solid tumors that have specific RAS-related gene changes (especially certain KRAS G12 mutations). You may be able to join if your tumor’s DNA test shows the right mutation and your overall health is good enough for study visits.
This trial tests a new pill, KST-6051, for people with advanced solid tumors (like lung, pancreatic, or colorectal cancer) that have a specific genetic change called a KRAS mutation. The goal is to see if the drug can shrink or control the cancer, and to find the best dose.
This trial tests a new pill (LY3962673) for people whose cancer has a specific DNA change called KRAS G12D. The drug aims to block the faulty protein that helps the cancer grow, and the study will look at safety and whether the tumor shrinks.
This trial tests an experimental drug (BMS-986523) alone or with other cancer treatments for people with advanced solid tumors that have a specific change in the KRAS gene. It aims to see if the drug is safe and effective.
Hear when a new KRAS Altered Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.